Jammu and Jammu are awaiting approval of new plant to ship high volumes of vaccines: execution

Johnson & Johnson is awaiting regulatory approval of a new, large plant operated by contract manufacturer Catalent Inc. to begin large-scale US delivery of its properly authorized COVID-19 vaccine after initial shipment this week, a top The Jammu and Kashmir executive said on Monday.

J&J will ship around 4 million doses of the one-shot vaccine around the United States this week and expects to deliver another 16 million doses later this month. But no one is expected to go out next week.

“The first dose comes from a small plant, which we could find earlier as well,” J&J Chief Scientific Officer Paul Stoffels said in an interview. “The big plant is on board, the FDA is looking at all the quality data and hopefully very soon, we will be able to get the ship approved from that plant and then we are leaving.”

Stoffels said he expected the catalytic plant to be approved within the next few days and that the company would be able to deliver on its promise to supply 20 million doses of the vaccine by the end of March.

Catalan North America President Mike Mike Riley stated, “The Johnson & Johnson catalog is on track to meet our commitments for COVID-19 vaccine delivery. As soon as we are approved by the FDA to begin shipment. in a statement.

Jammu and Kashmir is also working to expand its manufacturing capacity globally and is in talks with potential new partners, Stoffels said, adding that he hopes to be able to announce more manufacturing deals soon is.

While the company J&J is shooting 1 billion doses using existing capacity and bringing it online before the end of the year, Stoffels said, “More will be needed, and that’s what collaboration with our partners will require , To extend even further. “

“Those discussions are going on,” he said.

Those plans include an expansion in India, where the company is working this year to bring a plant with a higher capacity that will “serve a much larger part of the world”, Stoffels said.

The managing director of the Indian pharmaceutical company Biological E Ltd told Reuters last month that his company was seeking to contract about 600 million doses of the COVID-19 vaccine annually in Jammu and Kashmir.